^
Association details:
| Biomarker: | Chr del(5q) |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Regimen: | (bortezomib + dexamethasone injection + lenalidomide) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
Published date:
05/11/2023
Excerpt:
We aim to report our experience with lenalidomide, bortezomib and dexamethasone therapy in a patient with MDS del(5q) and MM….She tolerated lenalidomide 10 mg daily, bortezomib 1.3 mg/m2 and dexamethasone once weekly of a 28-day cycle, with no treatment related complications. Reassessment of bone marrow following 6 cycles of treatment showed a partial response for MM and complete response for MDS.
